Drugs / nL-SAA1-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06397001 | Nov 2023 → Dec 2024 | AA amyloidosis | Nelson Leung, MD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nL-SAA1-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06397001 ↗ |
| Modality | Antisense oligonucleotide | “Personalized antisense oligonucleotide” NCT06397001 ↗ |
| Route | Subcutaneous | “subcutaneous injection of nL-SAA1-01” NCT06397001 ↗ |